Immunological assessment of Benznidazol therapy in chronic chagas disease;Evaluación inmunológica del tratamiento con benznidazol en la enfermedad de Chagas crónica

Revista Argentina de Cardiologia

Volumn 76, Issue 4, 2008, Pages 260-265

  Bertocchi, Graciela L ^a,d   Álvarez, María G ^a   Pérez, Damián ^b   Armenti, Alejandro ^a   Viotti, Rodolfo J ^a   Lococo, Bruno ^a   Petti, Marcos ^a   Postan, Miriam ^b   Albareda, María C ^b   Laucella, Susana A ^b   Tarleton, Rick L ^c  

^a Hospital Eva Peron   (Argentina)

^b Instituto Nacional de Diagnostico e Investigacion de la Enfermedad de Chagas Dr Mario Fatala Chaben   (Argentina)

^c UNIVERSITY OF GEORGIA   (United States)

^d NONE   (Argentina)

Author keywords

Benznidazol; Chagas disease; Lymphocytes; Trypanosoma cruzi

Indexed keywords

EID: 58149116494     PISSN: 00347000     EISSN: 18503748     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. World Health Organization. Control of Chagas disease. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 2002;905:1-109.
2. Manzullo EC, Chuit R. Risk of death due to chronic chagasic cardiopathy. Mem Inst Oswaldo Cruz 1999;94:317-20.
3. Bestetti RB, Dalbo CM, Freitas OC, Teno LA, Castilho OT, Oliveira JS. Noninvasive predictors of mortality for patients with Chagas' heart disease: a multivariate stepwise logistic regression study. Cardiology 1994;84:261-7.
4. Cancado JR. Tratamento especifico. En: Cancado JR, Chuster M, editores. Cardiopatia Chagásica. Belo Horizonte, Brazil: Fundacao Carlos Chagas; 1985:327-55.
5. Tarleton RL, Zhang L. Chagas disease etiology: autoimmunity or parasite persistence? Parasitol Today 1999;15:94-9.
6. Tarleton RL. Parasite persistence in the aetiology of Chagas disease. Int J Parasitol 2001;31:550-4.
7. Urbina JA. Chemotherapy of Chagas' disease: the how and the why. J Mol Med 1999;77:332-8.
8. Khaw M, Panosian CB. Human antiprotozoal therapy: past, present, and future. Clin Microbiol Rev 1995;8:427-39.
9. Viotti R, Vigliano C, Armenti H, Segura E. Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. Am Heart J 1994;127:151-62.
10. Cancado JR. Long term evaluation of etiological treatment of Chagas disease with benznidazole. Rev Inst Med Trop Sao Paulo 2002;44:29-37.
11. Sosa-Estani S, Armenti A, Araujo G, Viotti R, Lococo B, Ruiz Vera B, et al. Treatment of Chagas disease with benznidazole and thioctic acid. Medicina (B Aires) 2004;64:1-6.
12. Fabbro De Suasnábar D, Arias E, Streiger M, Piacenza M, Ingaramo M, Del Barco M, et al. Evolutive behavior towards cardiomyopathy of treated (nifurtimox or benznidazole) and untreated chronic chagasic patients. Rev Inst Med Trop Sao Paulo 2000;42:99-109.
13. Fabbro DL, Streiger ML, Arias ED, Bizai ML, del Barco M, Amicone NA. Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean followup of 21 years: parasitological, serological and clinical evolution. Rev Soc Bras Med Trop 2007;40:1-10.
14. Rassi A, Luquetti AO. Specific treatment for Trypanosoma cruzi infection (Chagas disease). En: Tyler KM, Miles MA, editors. American Trypanosomiasis. Boston: Kluwer Academic Publishers; 2003. p. 117-25.
15. Laucella SA, Segura EL, Riarte A, Sosa ES. Soluble platelet selectin (sP-selectin) and soluble vascular cell adhesion molecule-1 (sVCAM-1) decrease during therapy with benznidazole in children with indeterminate form of Chagas' disease. Clin Exp Immunol 1999;118:423-7.
16. Olivieri BP, Cotta-De-Almeida V, Araújo-Jorge T. Benznidazole treatment following acute Trypanosoma cruzi infection triggers CD8+ T-cell expansion and promotes resistance to reinfection. Antimicrob Agents Chemother 2002;46:3790-6.
17. Laucella SA, Postan M, Martin D, Hubby Fralish B, Albareda MC, Alvarez MG, et al. Frequency of interferon- gamma -producing T cells specific for Trypanosoma cruzi inversely correlates with disease severity in chronic human Chagas disease. J Infect Dis 2004;189:909-18.
18. Albareda MC, Laucella SA, Alvarez MG, Armenti AH, Bertochi G, Tarleton RL, et al. Trypanosoma cruzi modulates the profile of memory CD8+ T cells in chronic Chagas' disease patients. Int Immunol 2006;18:465-71.
19. Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, Alvarez MG, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med 2006;144:724-34.
20. Kuschnir E, Sgammini H, Castro R, Evequoz C, Ledesma R, Brunetto J. Evaluation of cardiac function by radioisotopic angiography, in patients with chronic Chagas cardiopathy. Arq Bras Cardiol 1985;45:249-56.
21. Barclay CA, Cerisola JA, Lugones H, Ledesma O, Lopez Silva J, Mouzo G. Aspectos farmacológicos y resultados terapéuticos del benznidazol en el tratamiento de la infección chagásica. Prens Med Arg 1978; 65:239.
22. Zimmerli SC, Harari A, Cellerai C, Vallelian F, Bart PA, Pantaleo G. HIV-1-specific IFN-gamma/IL-2-secreting CD8 T cells support CD4-independent proliferation of HIV-1-specific CD8 T cells. Proc Natl Acad Sci U S A 2005;102:7239-44.
23. Harari A, Vallelian F, Meylan PR, Pantaleo G. Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. J Immunol 2005;174:1037-45.
24. Harari A, Dutoit V, Cellerai C, Bart PA, Du Pasquier RA, Pantaleo G. Functional signatures of protective antiviral T-cell immunity in human virus infections. Immunol Rev 2006;211:236-54.
25. Viotti R, Vigliano C, Armenti A. A risk score for predicting death in Chagas' heart disease. N Engl J Med 2006;355:2489.
26. Alvarez MG, Postan M, Weatherly B, Armenti A, Sidney J, Sette A, et al. HLA Class I-T cell epitopes from trans-sialidase proteins reveal functionally distinct subsets of CD8+ T cells specific for Trypanosoma cruzi in chronic Chagas disease. PLoS Neglected Tropical Diseases (in press).
27. Pantaleo G, Harari A. Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases. Nat Rev Immunol 2006;6:417-23.
28. Romanha AJ, Alves RO, Murta SM, Silva JS, Ropert C, Gazzinelli RT. Experimental chemotherapy against Trypanosoma cruzi infection: essential role of endogenous interferon-gamma in mediating parasitologic cure. J Infect Dis 2002;186:823-8.
29. Olivieri BP, de Souza AP, Cotta-de-Almeida V, de Castro SL, Araújo- Jorge T. Trypanosoma cruzi: alteration in the lymphoid compartments following interruption of infection by early acute benznidazole therapy in mice. Exp Parasitol 2006;114:228-34.
30. Dantas AP, Olivieri BP, Gomes FH, De Castro SL Treatment of Trypanosoma cruzi-infected mice with propolis promotes changes in the immune response. J Ethnopharmacol 2006;103:187-93.